1NVO : Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
Novo Nordisk’s Worst Month Since 2002 Highlights Growth Concerns
As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.
Fierce Pharma9h
FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
BioSpace12h
Novo Paints ‘Complicated’ Cardio Picture for Semaglutide Franchise
According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...
FMIBlog17h
Global Diabetes Care Devices Market to Surge to USD 117.7 Billion by 2034, Driven by Technological Innovations and Rising Diabetes Prevalence | FMI
The global diabetes care devices market is poised for substantial expansion, with projections indicating a rise from USD 64.5 billion in 2024 to an impressive USD 117.7 billion by 2034. The market’s ...